PMID- 19916063
OWN - NLM
STAT- MEDLINE
DCOM- 20100223
LR  - 20211020
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 208
IP  - 2
DP  - 2010 Feb
TI  - Amphetamine analogs methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) 
      differentially affect speech.
PG  - 169-77
LID - 10.1007/s00213-009-1715-0 [doi]
AB  - RATIONALE: Most reports of the effects of methamphetamine and 
      3,4-methylenedioxymethamphetamine (MDMA) on speech have been anecdotal. 
      OBJECTIVES: The current study used a within-participant design to assess the 
      effects of methamphetamine and MDMA on speech. MATERIALS AND METHODS: Eleven 
      recreational users of amphetamines completed this inpatient, within-participant, 
      double-blind study, during which they received placebo, methamphetamine (20, 40 
      mg), and MDMA (100 mg) on separate days. Following drug administration, study 
      participants described movies viewed the previous evening and completed mood 
      scales. RESULTS: Methamphetamine increased quantity of speech, fluency, and 
      self-ratings of talkativeness and alertness, while it decreased the average 
      duration of nonjuncture unfilled pauses. MDMA decreased fluency and increased 
      self-ratings of inability to concentrate. To determine if methamphetamine- and 
      MDMA-related effects were perceptible, undergraduates listened to the 
      participants' movie descriptions and rated their coherence and the speaker's 
      mood. Following methamphetamine, descriptions were judged to be more coherent and 
      focused than they were following MDMA. CONCLUSIONS: Methamphetamine improved 
      verbal fluency and MDMA adversely affected fluency. This pattern of effects is 
      consistent with the effects of these drugs on functioning in other cognitive 
      domains. In general, methamphetamine effects on speech were inconsistent with 
      effects popularly attributed to this drug, while MDMA-related effects were in 
      agreement with some anecdotal reports and discordant with others.
FAU - Marrone, Gina F
AU  - Marrone GF
AD  - Division of Substance Abuse, New York State Psychiatric Institute, 1051 Riverside 
      Dr., Unit 120, New York, NY 10032, USA.
FAU - Pardo, Jennifer S
AU  - Pardo JS
FAU - Krauss, Robert M
AU  - Krauss RM
FAU - Hart, Carl L
AU  - Hart CL
LA  - eng
GR  - R01 DA03746/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20091117
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Central Nervous System Stimulants)
RN  - 44RAL3456C (Methamphetamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/blood/*pharmacology
MH  - Adult
MH  - Affect/drug effects
MH  - Arousal/drug effects
MH  - Attention/drug effects
MH  - Central Nervous System Stimulants/blood/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Methamphetamine/blood/*pharmacology
MH  - Self Concept
MH  - Speech/*drug effects
MH  - Speech Intelligibility/drug effects
MH  - Young Adult
EDAT- 2009/11/17 06:00
MHDA- 2010/02/24 06:00
CRDT- 2009/11/17 06:00
PHST- 2009/06/15 00:00 [received]
PHST- 2009/10/27 00:00 [accepted]
PHST- 2009/11/17 06:00 [entrez]
PHST- 2009/11/17 06:00 [pubmed]
PHST- 2010/02/24 06:00 [medline]
AID - 10.1007/s00213-009-1715-0 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2010 Feb;208(2):169-77. doi: 
      10.1007/s00213-009-1715-0. Epub 2009 Nov 17.